{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', 'Employees who are not blinded to drug assignment will have no access to any other subject-level', 'information for the duration of the study. Sponsor employees interacting with sites will remain', 'blinded for Part 2 of the study; however, unblinding of these staff may occur out of necessity', 'during document preparation for regulatory filings of the study.', 'The bioanalytical laboratory performing BCX7353 plasma concentration analysis may be given a', 'copy of the randomization scheme.', 'Information on unblinding in the event of an SAE is provided in Section 12.1.9.', '9.3.2.', 'Randomization', 'Subjects will be randomized via interactive (web or voice) response system (IXRS). Details on', 'the processes to be followed for randomization will be provided in a separate manual.', '9.3.2.1.', 'Part 1 Randomization', 'Approximately 24 subjects will be randomized in a 1:1:1 (active:active:placebo) ratio to the', 'following treatments in Part 1:', 'Treatment Group 1: BCX7353 110 mg administered orally QD for 24 weeks', 'Treatment Group 2: BCX7353 150 mg administered orally QD for 24 weeks', 'Treatment Group 3: placebo administered orally QD for 24 weeks', 'Randomization will proceed in accordance with a computer-generated randomization schedule', 'prepared by an unblinded statistician.', 'Sites will randomize eligible subjects in the IXRS, preferably after all baseline assessments to', 'reconfirm eligibility have been completed. If required by site procedures (ie, dispensing of', 'randomized study drug must occur through a pharmacy), the subject may be randomized on the', 'business day prior to the planned baseline visit.', 'The sponsor may require review of screening data prior to randomizing a subject', '(eg, concomitant medications); any requirements will be provided to the site separately.', 'Enrollment into treatment groups will be stratified by the qualifying angioedema event rate at', 'baseline (> 2 angioedema events per month VS. < 2 angioedema events per month) entered into', 'the IXRS at the time of randomization. The baseline angioedema event rate must be provided', 'during randomization and is calculated by:', '(the number of angioedema events meeting the criteria of an angioedema event below from', 'the screening visit through the time of randomization X 28) divided by the number of days', 'during the timeframe from the screening visit through randomization, rounded up to', '2 decimal places', 'Angioedema events to be utilized in calculation of the baseline angioedema event rate must meet', 'the following criteria:', 'The angioedema events must be unique, which is defined as an angioedema event that', 'does not begin within 48 hours of the end of a previous angioedema event.', '49']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', 'The angioedema events must have either been treated, required medical attention, or', 'be documented to cause functional impairment based on subject entry in the e-diary.', 'Functional impairment is defined as the subject being unable to perform his or her', 'daily activities without restriction (ie, subject records that he or she is at least slightly', 'restricted in daily activities during the angioedema event).', 'The angioedema events must include symptoms of swelling. The expert will consider', 'that symptoms of swelling, in addition to visible swelling, may also include', 'symptoms in the oropharyngeal or abdominal regions that are indicative of internal', 'swelling.', 'The angioedema events must be confirmed by an independent expert to be', 'angioedema events, based upon the e-diary record and investigator-collected', 'information.', '9.3.2.2.', 'Part 2 Randomization', 'Subjects who received active BCX7353 in Part 1 of the study (treatment Groups 1 and 2) will', 'continue to receive the same dosing regimen in Part 2. Subjects who received placebo (treatment', 'Group 3) during Part 1 will be randomized in a 1:1 ratio to receive a 110 or 150 mg QD dose of', 'BCX7353 during Part 2.', 'Subjects who received placebo during Part 1 will be automatically randomized for Part 2 in the', 'IXRS, which will occur at the time of the Week 24 visit (Figure 2). Sites will assign drug for', 'Part 2 of the study in the IXRS beginning at the Week 24 visit.', 'Note: Sites will assign 150 mg kits in Part 3 of the study in the IXRS beginning at Week 52.', 'Sites using a centralized pharmacy may assign drug to a subject the day prior to a study visit.', 'Figure 2:', 'Study Randomization', 'Part 3 dosing: Week 52 up to Week 104', 'Part 1 dosing: Day 1 to Week 24', 'Part 2 dosing: Weeks 24 to 52', '(Days 366 to 729) or until such time as', '(Day 168)', '(Days 169 to 365)', 'BCX7353 is commercially available*', '110 mg BCX7353 QD', '110 mg BCX7353 QD', '150 mg BCX7353 QD', 'x 24 weeks (Group 1)', 'x 28 weeks (Group 1)', 'x 52 weeks', '150 mg BCX7353 QD', '150 mg BCX7353 QD', '150 mg BCX7353 QD', 'x 24 weeks (Group 2)', 'x 28 weeks (Group 2)', 'X 52 weeks', '1:1:1 ratio', '110 mg BCX7353 QD', '150 mg BCX7353 QD', 'x 28 weeks (Group 3a)', '52 weeks', 'Placebo QD x 24', '2nd randomization at', 'weeks (Group 3)', 'Week 24:1:1 ratio', '150 mg BCX7353 QD', '150 mg BCX7353 QD', 'x 28 weeks (Group 3b)', 'x 52 weeks', 'Abbreviations: QD = once daily.', '* In the event that BCX7353 is not commercially available when the first and each subsequent subject at each site', 'reaches Week 104, then the treatment period will be extended with additional telephone contacts conducted at', '4-week intervals (Weeks 108, 112, etc.) and clinic visits completed at 12-week intervals (Week 116, etc.) to allow', 'the subject to continue treatment with BCX7353 until commercially available, unless the subject discontinues his', 'or her participation in the study. After marketing authorization, BCX7353 will be administered at the dose regimen', 'that is approved in Japan.', '50']\n\n###\n\n", "completion": "END"}